Multiple cases of sensitization to an antiseptic containing chlorhexidine digluconate/benzalkonium chloride/benzyl alcohol with different profiles of sensitization in adults and children.


Journal

Contact dermatitis
ISSN: 1600-0536
Titre abrégé: Contact Dermatitis
Pays: England
ID NLM: 7604950

Informations de publication

Date de publication:
Jul 2022
Historique:
revised: 09 02 2022
received: 13 11 2021
accepted: 10 02 2022
pubmed: 26 2 2022
medline: 15 6 2022
entrez: 25 2 2022
Statut: ppublish

Résumé

An aqueous antiseptic containing "chlorhexidine digluconate/benzalkonium chloride/benzyl alcohol" (CBB) is widely used in France. The only previous documented study dealing with allergic contact dermatitis (ACD) to this antiseptic is one small case series in children. The French Vigilance Network for Dermatology and Allergy (REVIDAL-GERDA) has collected many cases in the last few years. To evaluate the clinical and sensitization profiles of patients diagnosed with ACD to CBB. We performed a retrospective study of patients with contact dermatitis to CBB and positive tests to CBB and/or at least one of its components. All patients had to be tested with all components of CBB. A total of 102 patients (71 adults and 31 children) were included. The lesions were extensive in 63% of patients and 55% had delayed time to diagnosis. CBB patch tests were positive in 93.8% of cases. The allergen was identified in 97% of patients, mainly benzyl alcohol in adults (81.7%) and chlorhexidine digluconate in children (54.8%). About 32.4% of the patients were sensitized to several components. CBB is a cause of ACD at all ages. The components of the antiseptic should be tested. The sensitization profile seems to be different between adults and children.

Sections du résumé

BACKGROUND BACKGROUND
An aqueous antiseptic containing "chlorhexidine digluconate/benzalkonium chloride/benzyl alcohol" (CBB) is widely used in France. The only previous documented study dealing with allergic contact dermatitis (ACD) to this antiseptic is one small case series in children. The French Vigilance Network for Dermatology and Allergy (REVIDAL-GERDA) has collected many cases in the last few years.
OBJECTIVES OBJECTIVE
To evaluate the clinical and sensitization profiles of patients diagnosed with ACD to CBB.
METHODS METHODS
We performed a retrospective study of patients with contact dermatitis to CBB and positive tests to CBB and/or at least one of its components. All patients had to be tested with all components of CBB.
RESULTS RESULTS
A total of 102 patients (71 adults and 31 children) were included. The lesions were extensive in 63% of patients and 55% had delayed time to diagnosis. CBB patch tests were positive in 93.8% of cases. The allergen was identified in 97% of patients, mainly benzyl alcohol in adults (81.7%) and chlorhexidine digluconate in children (54.8%). About 32.4% of the patients were sensitized to several components.
CONCLUSION CONCLUSIONS
CBB is a cause of ACD at all ages. The components of the antiseptic should be tested. The sensitization profile seems to be different between adults and children.

Identifiants

pubmed: 35213760
doi: 10.1111/cod.14085
doi:

Substances chimiques

Allergens 0
Anti-Infective Agents, Local 0
Benzalkonium Compounds 0
Benzyl Alcohols 0
Chlorides 0
chlorhexidine gluconate MOR84MUD8E
Chlorhexidine R4KO0DY52L

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

62-70

Informations de copyright

© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

McDonnell G, Russell AD. Antiseptics and disinfectants: activity, action, and resistance. Clin Microbiol Rev. 1999;12(1):147-179.
Marks JG. Allergic contact dermatitis to povidone-iodine. J Am Acad Dermatol. 1982;6(4):473-475.
Erdmann S, Hertl M, Merk HF. Allergic contact dermatitis from povidone-iodine. Contact Dermatitis. 1999;40(6):331-332.
Lachapelle JM. Allergic contact dermatitis from povidone-iodine: a re-evaluation study. Contact Dermatitis. 2005;52(1):9-10.
Velázquez D, Zamberk P, Suárez R, Lázaro P. Allergic contact dermatitis to povidone Iodine. Contact Dermatitis. 2009;60(6):348-349.
Barbaud A, Collet E, Le Coz CJ, Meaume S, Gillois P. Contact allergy in chronic leg ulcers: results of a multicentre study carried out in 423 patients and proposal for an updated series of patch tests. Contact Dermatitis. 2009;60(5):279-287.
Barbaud A, Vigan M, Delrous JL, et al. Contact allergy to antiseptics: 75 cases analyzed by the dermato-allergovigilance network (Revidal). Ann Dermatol Venereol. 2005;132(12Pt1):962-965.
Robin J. Contact dermatitis to hexamidine. Contact Dermatitis. 1978;4(6):375-376.
Revuz J, Poli F, Wechsler J, Dubertret L. Contact dermatitis from hexamidine. Ann Dermatol Venereol. 1984;111(9):805-810.
Dooms-Goossens A, Vandaele M, Bedert R, Marien K. Hexamidine isethionate: a sensitizer in topical pharmaceutical products and cosmetics. Contact Dermatitis. 1989;21(4):270.
Magdaleno-Tapial J, Martínez-Doménech A, Valenzuela-Oñate C, Ferrer-Guillén B, Esteve-Martínez A, Zaragoza-Ninet V. Allergic contact dermatitis to chlorhexidine in pediatric patients. Pediatr Dermatol. 2019;36(4):540-541.
Mailhol C, Lauwers-Cances V, Rancé F, Paul C, Giordano-Labadie F. Prevalence and risk factors for allergic contact dermatitis to topical treatment in atopic dermatitis: a study in 641 children. Allergy. 2009;64(5):801-806.
De Waard-van der Spek FB, Oranje AP. Allergic contact dermatitis to chlorhexidine and Para-amino compounds in a 4-year-old boy: a very rare observation. Contact Dermatitis. 2008;58(4):239-241.
Uter W, Lessmann H, Geier J, Schnuch A. Is the irritant Benzalkonium chloride a contact allergen? A contribution to the ongoing debate from a clinical perspective. Contact Dermatitis. 2008;58(6):359-363.
Basketter DA, Marriott M, Gilmour NJ, White IR. Strong irritants masquerading as skin allergens: the case of benzalkonium chloride. Contact Dermatitis. 2004;50(4):213-217.
Wentworth AB, Yiannias JA, Davis MD, Killian JM. Benzalkonium chloride: a known irritant and novel allergen. Dermatitis. 2016;27(1):14-20.
Isaac J, Scheinman PL. Benzalkonium Chloride: an Irritant and Sensitizer. Dermatitis. 2017;28(6):346-352.
Zhang AJ, Boyd AH, Schlarbaum JP, Warshaw EM. Allergic contact dermatitis secondary to the use of a bandage impregnated with benzalkonium chloride. Contact Dermatitis. 2018;79(6):387-388.
Tartari F, Vincenzi C, Di Altobrando A, Bruni F, Neri I. Allergic contact dermatitis to benzalkonium chloride with erythema multiforme-like reaction in a child. Contact Dermatitis. 2020;82(6):397-399.
Schnuch A, Uter W, Geier J, Lessmann H, Frosch PJ. Sensitization to 26 fragrances to be labelled according to current European regulation. Results of the IVDK and review of the literature. Contact Dermatitis. 2007;57(1):1-10.
Jacob SE, Stechschulte S. Eyelid dermatitis associated with balsam of Peru constituents: benzoic acid and benzyl alcohol. Contact Dermatitis. 2008;58(2):111-112.
Podda M, Zollner T, Grundmann-Kollmann M, Kaufmann R, Boehncke WH. Allergic contact dermatitis from benzyl alcohol during topical antimycotic treatment. Contact Dermatitis. 1999;41(5):302-303.
Sestini S, Mori M, Francalanci S. Allergic contact dermatitis from benzyl alcohol in multiple medicaments. Contact Dermatitis. 2004;50(5):316-317.
Kubin ME, Riekki R. Benzyl alcohol allergy mimicking corticosteroid allergy. Contact Dermatitis. 2016;75(1):58-59.
Mitchell DM, Beck MH. Contact allergy to benzyl alcohol in a cutting oil reodorant. Contact Dermatitis. 1988;18(5):301-302.
Carrascosa JM, Domingo H, Soria X, Ferrándiz C. Allergic contact dermatitis due to benzyl alcohol in a hair dye. Contact Dermatitis. 2006;55(2):124-125.
Opstrup MS, Johansen JD, Zachariae C, Garvey LH. Contact allergy to chlorhexidine in a tertiary dermatology Clinic in Denmark. Contact Dermatitis. 2016;74(1):29-36.
Toholka R, Nixon R. Allergic contact dermatitis to chlorhexidine. Australas J Dermatol. 2013;54(4):303-306.
DeKoven JG, Warshaw EM, Zug KA, et al. North American contact dermatitis group patch test results: 2015-2016. Dermatitis. 2018;29(6):297-309.
Darrigade AS, Léauté-Labrèze C, Boralevi F, Taïeb A, Milpied B. Allergic contact reaction to antiseptics in very young children. J Eur Acad Dermatol Venereol. 2018;32(12):2284-2287.
Le Corre Y, Barbarot S, Frot AS, Milpied B. Allergic contact dermatitis to chlorhexidine in a very young child. Pediatr Dermatol. 2010;27(5):485-487.
Andersen KE, Rycroft RJG. Recommended patch test concentrations for preservatives, biocides and antimicrobials. Contact Dermatitis. 1991;25(1):1-18.
Bohaty B, Fricker C, González S, Gill M, Nedorost S. Visual and confocal microscopic interpretation of patch tests to benzethonium chloride and benzalkonium chloride. Skin Res Technol. 2012;18(3):272-277.
Galadari A, Darrigade AS, Boralevi F, Milpied B. A child polysensitized to all constituents of Biseptine. Contact Dermatitis. 2020;82(1):65-66.
Flament J, Bauvin O, Tétart F. Allergies de contact à la BISEPTINE®: il n'y a pas que la chlorhexidine. Rev Fr Allergol. 2018;58(3):262.
Jacob SE, Barron GS. Benzyl alcohol: a covert fragrance. Dermatitis. 2007;18(4):232-233.
Rastogi S, Patel KR, Singam V, Silverberg JI. Allergic contact dermatitis to personal care products and topical medications in adults with atopic dermatitis. J Am Acad Dermatol. 2018;79(6):1028-1033.
Kadivar S, Belsito DV. Occupational dermatitis in health care workers evaluated for suspected allergic contact dermatitis. Dermatitis. 2015;26(4):177-183.
Om A, Yeung H, de la Feld S. Prevalence of contact allergens in best-selling ophthalmic products. Dermatitis. 2021;32(4):273-279.

Auteurs

Charlotte Beaumont (C)

Department of Dermatology, Hôpital Estaing, CHU Clermont-Ferrand, Clermont-Ferrand, France.

Anne-Sophie Darrigade (AS)

Department of Dermatology, Hôpital Saint-André, CHU Bordeaux, Bordeaux, France.

Annick Barbaud (A)

Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP.Sorbonne Université, Hôpital Tenon, Département de dermatologie et allergologie, Paris, France.

Evelyne Collet (E)

Department of Dermatology, CHU Dijon-Bourgogne, Dijon, France.

Nadia Raison-Peyron (N)

Department of Dermatology, Hôpital Saint Eloi, CHU Montpellier, Montpellier, France.

Jean-Luc Bourrain (JL)

Department of Pneumology and Allergology, CHU Montpellier, Montpellier, France.

Haudrey Assier (H)

Department of Dermatology, CHU Henri Mondor, Créteil, France.

Françoise Giordano-Labadie (F)

Department of Dermatology, Hôpital Larrey, CHU Toulouse, Toulouse, France.

Corina Bara-Passot (C)

Department of Dermatology, CHM, Le Mans, France.

Brigitte Milpied (B)

Department of Dermatology, Hôpital Saint-André, CHU Bordeaux, Bordeaux, France.

Florence Tétart (F)

Department of Allergology, Centre Erik Satie, CHU Rouen, Rouen, France.

Pierre Armingaud (P)

Private Dermatology Practice, Orléans, France.

Florence Castelain (F)

Department of Dermatology, Hôpital Jean Minjoz, CHU Besançon, Besançon, France.

Lamia Benkalfate (L)

Private Dermatology Practice, Rennes, France.

Claire Boulard (C)

Department of Dermatology, Hôpital Jacques Monod, CH Le Havre, Montivilliers, France.

Juliette Delaunay (J)

Department of Dermatology, CHU Angers, Angers, France.

Pascale Mathelier-Fusade (P)

Sorbonne Université, AP-HP, Hôpital Tenon, Département de dermatologie et allergologie, Paris, France.

Catherine Pecquet (C)

Sorbonne Université, AP-HP, Hôpital Tenon, Département de dermatologie et allergologie, Paris, France.

Pauline Pralong (P)

Department of Dermatology, Hôpital Nord, CHU Grenoble, La Tronche, France.

Dominique Vital-Durand (D)

Department of Dermatology, Hôpital Edouard Herriot, CHU Lyon, Lyon, France.

Nathalie Genillier Foin (N)

Private Dermatology Practice, Bayonne, France.

Marine-Alexia Lefèvre (MA)

Department of Dermatology and Allergology, CHU Saint-Etienne, Saint Priest-en-Jarrez, France.

Florence Hacard (F)

Department of Allergology and Immunology, CHU Lyon Sud, Pierre Bénite, France.

Audrey Nosbaum (A)

Department of Allergology and Immunology, CHU Lyon Sud, Pierre Bénite, France.

Justine Pasteur (J)

Department of Dermatology, Hôpital Estaing, CHU Clermont-Ferrand, Clermont-Ferrand, France.

Aude Valois (A)

Department of Dermatology, Hôpital d'instruction des armées Sainte Anne, Toulon, France.

Martine Vigan (M)

Department of Dermatology, Hôpital Jean Minjoz, CHU Besançon, Besançon, France.

Marie-Christine Ferrier le Bouëdec (MC)

Department of Dermatology, Hôpital Estaing, CHU Clermont-Ferrand, Clermont-Ferrand, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH